Continuous Biologics Manufacturing Integration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The biologics manufacturing process is inefficient due to duplicated efforts, increased costs, material waste, and potential drug substance loss and destabilization caused by redundant filtration steps and freeze/thaw operations, which are not compatible with continuous manufacturing platforms.
Innovation Solution
An integrated, continuous method for producing recombinant biologic therapeutics that eliminates or combines steps from ultrafiltration and diafiltration (UFDF) through drug product fill/finish, including in-line addition of stability-enhancing excipients and reduced bioburden filtration, without freezing and thawing unit operations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If traditional two-part process with freeze/thaw steps is used, then drug substance can be stored and transported, but manufacturing time increases and drug substance stability deteriorates
Solution Approach 1:
The patent implements continuous manufacturing by eliminating discrete freeze/thaw cycles and intermediate storage steps. The process flows continuously from purification through UFDF, excipient addition, filtration, and fill/finish without interruption, maintaining drug substance stability while reducing manufacturing time.
Solution Approach 2:
The patent extracts and eliminates the harmful freeze/thaw unit operations from the manufacturing process. By removing these disruptive steps while maintaining necessary storage and transport capabilities through continuous flow design, the process improves both stability and time efficiency.
2Reliability
If redundant filtration steps and multiple hold/store steps are used, then bioburden reduction and quality control are improved, but equipment complexity increases and material waste increases
Solution Approach 1:
The patent merges multiple filtration and hold steps into an integrated continuous process. The single-pass filtration system combines bioburden reduction and sterile filtration functions, while continuous flow eliminates the need for multiple hold vessels, reducing equipment complexity while maintaining reliability.
Solution Approach 2:
The continuous manufacturing system performs multiple functions simultaneously: UFDF concentrates and formulates while reducing bioburden, the same stream receives excipients, and a single filtration step achieves both bioburden reduction and sterile filtration, eliminating the need for separate dedicated equipment for each function.
3Stability of the object's composition
If multiple hold/store steps and freeze/thaw operations are used, then drug substance can be stored and transported, but drug substance loss increases
Solution Approach 1:
The continuous manufacturing process eliminates intermediate storage and transfer steps where drug substance loss typically occurs. By maintaining continuous flow from purification through final fill, the system minimizes exposure to conditions that cause degradation and eliminates transfer losses associated with freeze/thaw operations.
Solution Approach 2:
The patent extracts and removes the freeze/thaw unit operations that cause drug substance loss through precipitation, aggregation, and adsorption to container surfaces. The continuous process maintains drug substance in solution throughout, eliminating these loss mechanisms while preserving stability.
4Reliability
If traditional batch processing with multiple steps is used, then quality control can be performed at each stage, but manufacturing cost increases
Solution Approach 1:
The continuous manufacturing process enables real-time quality control through continuous monitoring of critical parameters throughout the process. This eliminates the need for repeated batch testing and reprocessing, reducing manufacturing costs while maintaining or improving quality control through continuous data collection and process control.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach reduces manufacturing costs, minimizes equipment and material usage, and enhances process efficiency by streamlining the production process, reducing waste, and maintaining protein stability, thereby supporting modular and flexible facility design and just-in-time manufacturing.
Implementation Method 1
concentrating or diluting the purified recombinant protein by ultrafiltration
Implementation Method 2
buffer exchanging the purified recombinant protein into a desired formulation by diafiltration
Implementation Method 3
subjecting the resulting bulk drug substance to filtration to reduce bioburden
Implementation Method 4
subjecting the resulting bulk drug product to sterile filtration
Data Source
AI summary
A biologics manufacturing process that connects the drug substance and drug product processes into an integrated, continuous process.